(FME) Fresenius Medical Care - Ratings and Ratios
Dialysis,Machines,Dialyzers,Concentrates,Solutions
FME EPS (Earnings per Share)
FME Revenue
Description: FME Fresenius Medical Care
Fresenius Medical Care AG is a leading provider of dialysis and related services for patients with renal diseases, operating globally with a significant presence in Germany and the United States. The companys comprehensive offerings include outpatient dialysis clinics, laboratory and diagnostic services, and a range of healthcare products such as dialyzers, hemodialysis machines, and renal pharmaceuticals.
The companys business model is diversified across various revenue streams, including dialysis treatment services, product sales to dialysis clinics and hospitals, and the provision of related laboratory and diagnostic services. Fresenius Medical Care AG has a strong global footprint, with a significant market share in the dialysis industry.
From a financial perspective, Fresenius Medical Care AG has a market capitalization of approximately €13.87 billion, indicating a substantial presence in the healthcare sector. Key performance indicators (KPIs) such as revenue growth, EBITDA margins, and return on equity (ROE) are crucial in evaluating the companys financial health. With a reported ROE of 4.38%, the company demonstrates a relatively modest return on shareholders equity. The forward P/E ratio of 11.74 suggests that the market expects earnings growth in the future.
To further analyze the companys prospects, additional KPIs such as debt-to-equity ratio, interest coverage ratio, and operating cash flow margins can provide valuable insights into its financial stability and operational efficiency. Moreover, industry trends, competitive landscape, and regulatory factors will also impact Fresenius Medical Care AGs future performance. For instance, the growing prevalence of chronic kidney disease, advancements in dialysis technology, and changes in healthcare policies can influence the companys growth trajectory.
Given the companys diversified business model and global presence, a thorough analysis of its financials, industry trends, and competitive positioning is necessary to determine its investment potential. By examining key metrics and industry dynamics, investors can make informed decisions about Fresenius Medical Care AGs common stock (FME).
FME Stock Overview
| Market Cap in USD | 14,622m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception |
FME Stock Ratings
| Growth Rating | 41.9% |
| Fundamental | 58.8% |
| Dividend Rating | 26.4% |
| Return 12m vs S&P 500 | -0.83% |
| Analyst Rating | - |
FME Dividends
| Dividend Yield 12m | 3.36% |
| Yield on Cost 5y | 2.27% |
| Annual Growth 5y | -13.09% |
| Payout Consistency | 97.7% |
| Payout Ratio | 43.1% |
FME Growth Ratios
| Growth Correlation 3m | -83.4% |
| Growth Correlation 12m | 57% |
| Growth Correlation 5y | -54.3% |
| CAGR 5y | 17.79% |
| CAGR/Max DD 3y | 0.48 |
| CAGR/Mean DD 3y | 1.60 |
| Sharpe Ratio 12m | 1.34 |
| Alpha | 8.02 |
| Beta | 0.218 |
| Volatility | 30.46% |
| Current Volume | 398.8k |
| Average Volume 20d | 546.6k |
| Stop Loss | 41.2 (-3.1%) |
| Signal | -0.28 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (656.4m TTM) > 0 and > 6% of Revenue (6% = 1.17b TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 2.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.68% (prev 14.18%; Δ -1.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 2.75b > Net Income 656.4m (YES >=105%, WARN >=100%) |
| Net Debt (9.31b) to EBITDA (3.09b) ratio: 3.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (293.4m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 24.67% (prev 25.34%; Δ -0.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.88% (prev 57.28%; Δ 2.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.77 (EBITDA TTM 3.09b / Interest Expense TTM 392.3m) >= 6 (WARN >= 3) |
Altman Z'' 2.62
| (A) 0.08 = (Total Current Assets 8.14b - Total Current Liabilities 5.66b) / Total Assets 31.29b |
| (B) 0.36 = Retained Earnings (Balance) 11.29b / Total Assets 31.29b |
| (C) 0.05 = EBIT TTM 1.48b / Avg Total Assets 32.59b |
| (D) 0.59 = Book Value of Equity 9.93b / Total Liabilities 16.96b |
| Total Rating: 2.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.81
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 11.28% = 5.0 |
| 3. FCF Margin 10.52% = 2.63 |
| 4. Debt/Equity 0.60 = 2.33 |
| 5. Debt/Ebitda 2.56 = -1.07 |
| 6. ROIC - WACC 0.43% = 0.54 |
| 7. RoE 4.70% = 0.39 |
| 8. Rev. Trend -25.49% = -1.27 |
| 9. Rev. CAGR -2.22% = -0.37 |
| 10. EPS Trend -10.80% = -0.27 |
| 11. EPS CAGR -0.77% = -0.10 |
What is the price of FME shares?
Over the past week, the price has changed by +0.43%, over one month by -0.12%, over three months by -14.12% and over the past year by +17.28%.
Is Fresenius Medical Care a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FME is around 38.38 EUR . This means that FME is currently overvalued and has a potential downside of -9.69%.
Is FME a buy, sell or hold?
What are the forecasts/targets for the FME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.3 | 18.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 41.3 | -2.9% |
FME Fundamental Data Overview
Market Cap EUR = 12.47b (12.47b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 2.19b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 19.0583
P/E Forward = 9.9701
P/S = 0.6389
P/B = 0.9515
P/EG = 0.385
Beta = 0.878
Revenue TTM = 19.52b EUR
EBIT TTM = 1.48b EUR
EBITDA TTM = 3.09b EUR
Long Term Debt = 6.33b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.60b EUR (from shortTermDebt, last quarter)
Debt = 7.93b EUR (Calculated: Short Term 1.60b + Long Term 6.33b)
Net Debt = 9.31b EUR (from netDebt column, last quarter)
Enterprise Value = 18.21b EUR (12.47b + Debt 7.93b - CCE 2.19b)
Interest Coverage Ratio = 3.77 (Ebit TTM 1.48b / Interest Expense TTM 392.3m)
FCF Yield = 11.28% (FCF TTM 2.05b / Enterprise Value 18.21b)
FCF Margin = 10.52% (FCF TTM 2.05b / Revenue TTM 19.52b)
Net Margin = 3.36% (Net Income TTM 656.4m / Revenue TTM 19.52b)
Gross Margin = 24.67% ((Revenue TTM 19.52b - Cost of Revenue TTM 14.70b) / Revenue TTM)
Tobins Q-Ratio = 1.83 (Enterprise Value 18.21b / Book Value Of Equity 9.93b)
Interest Expense / Debt = 1.22% (Interest Expense 96.6m / Debt 7.93b)
Taxrate = 29.90% (316.1m / 1.06b)
NOPAT = 1.04b (EBIT 1.48b * (1 - 29.90%))
Current Ratio = 1.44 (Total Current Assets 8.14b / Total Current Liabilities 5.66b)
Debt / Equity = 0.60 (Debt 7.93b / last Quarter total Stockholder Equity 13.27b)
Debt / EBITDA = 2.56 (Net Debt 9.31b / EBITDA 3.09b)
Debt / FCF = 3.86 (Debt 7.93b / FCF TTM 2.05b)
Total Stockholder Equity = 13.96b (last 4 quarters mean)
RoA = 2.10% (Net Income 656.4m, Total Assets 31.29b )
RoE = 4.70% (Net Income TTM 656.4m / Total Stockholder Equity 13.96b)
RoCE = 7.30% (Ebit 1.48b / (Equity 13.96b + L.T.Debt 6.33b))
RoIC = 4.93% (NOPAT 1.04b / Invested Capital 21.03b)
WACC = 4.50% (E(12.47b)/V(20.40b) * Re(6.82%)) + (D(7.93b)/V(20.40b) * Rd(1.22%) * (1-Tc(0.30)))
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.03% ; FCFE base≈1.78b ; Y1≈1.75b ; Y5≈1.79b
Fair Price DCF = 108.3 (DCF Value 31.76b / Shares Outstanding 293.4m; 5y FCF grow -2.64% → 3.0% )
Revenue Correlation: -25.49 | Revenue CAGR: -2.22%
Rev Growth-of-Growth: 2.15
EPS Correlation: -10.80 | EPS CAGR: -0.77%
EPS Growth-of-Growth: 53.01